logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Tongce Medical: plans to acquire 100% equity of four subsidiaries, with a total transaction amount of 600 million yuan.

date
24/03/2026
6100%
Latest
3 m ago
According to a research report released by Open Source Securities on March 24th, Dana Bio (920009.SH) was given a "buy" rating. The main reasons for the rating include: 1) The company's early diagnosis specialty in invasive fungal diseases has a market share of over 30%; 2) The expanding demand for in vitro diagnostics, with the Chinese pathogenic microorganism diagnostic market expected to exceed one billion yuan by 2030; 3) The mortality rate of invasive fungal diseases is 27.6% and early diagnosis is crucial; 4) Dana Bio has two exclusive domestic products, a total of 91 domestic patents, and is involved in 10 major technology projects. (Daily Economic News)
4 m ago
Total will shift $1 billion in investments from wind power projects to a liquefied natural gas project in Texas.
4 m ago
Zhu Hexin met with Alexander Evans, CEO of HSBC Group.
4 m ago
Every AI's flash news, Cinda Securities announced on March 24th that it has given Baiyunshan (600332.SH) a "buy" rating in its research report. The main reasons for the rating include: 1) outstanding performance on the income side & pressure on pharmaceutical products, short-term pressure on 25Q4 quarterly profits; 2) comprehensive deployment of "internationalization + research and development innovation + external development + market value management". (Daily Economic News)
4 m ago
Agile Robotics Company has reached a partnership with Google DeepMind to inject intelligent capabilities into the field of robotics.
See all latestmore
logo
Contact US
qr
+852 - 60190728
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.